Cited 0 times in
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2021-09-29T01:34:09Z | - |
dc.date.available | 2021-09-29T01:34:09Z | - |
dc.date.issued | 2021-06 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184432 | - |
dc.description.abstract | Background/aim: Sorafenib is the first systemic therapy for the treatment of advanced-stage hepatocellular carcinoma (HCC) and progressive HCC after locoregional therapy. The aim of this study was to evaluate the prognostic factors of long-term survivors after sorafenib treatment. Methods: This multicenter, retrospective, cohort study included 1,566 unresectable HCC patients who received sorafenib treatment between 2007 and 2014 in nine tertiary centers in Korea. The patients were classified into a long-term survivor group (survival more than two years, n = 257) or a control group (n = 1309). The primary outcomes were the prognostic factors affecting long-term survival. Secondary endpoints included time-to-progression and other safety profiles. Results: The patients were predominantly men (83.8%) with chronic hepatitis B (77.3%) and Barcelona clinic of liver cancer-stage C (BCLC-C) (78.3%). The median overall survival was 9.0 months. After treatment, eight patients (0.4%) achieved complete response and 139 patients (8.8%) achieved partial response according to the mRECIST criteria. The prognostic factors predicting long-term survival were metformin use (adjusted hazard ratio [aHR] = 3.464; P < 0.001), hand-foot skin reaction (aHR = 1.688; P = 0.003), and concomitant treatment with chemoembolization or radiotherapy (aHR = 2.766; P < 0.001). Poor prognostic factors of long-term survival were a Child-Pugh score of B (HR = 0.422; P < 0.001), the presence of extrahepatic metastasis (HR = 0.639; P = 0.005), main portal vein invasion (HR = 0.502; P = 0.001), and elevated alpha-fetoprotein (>1,000 ng/mL; HR = 0.361; P < 0.001). Conclusion: This large, multicenter, retrospective study showed an objective response rate of 9.1% and a proportion of long-term survivors of 16.4% in Korean patients. The prognostic factors derived in our study can be used in clinical practice during sorafenib treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Dove Press | - |
dc.relation.isPartOf | JOURNAL OF HEPATOCELLULAR CARCINOMA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Young Youn Cho | - |
dc.contributor.googleauthor | Su Jong Yu | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Wonseok Kang | - |
dc.contributor.googleauthor | Yong-Han Paik | - |
dc.contributor.googleauthor | Pil Soo Sung | - |
dc.contributor.googleauthor | Si Hyun Bae | - |
dc.contributor.googleauthor | Su Cheol Park | - |
dc.contributor.googleauthor | Young Seok Doh | - |
dc.contributor.googleauthor | Kang Mo Kim | - |
dc.contributor.googleauthor | Eun Sun Jang | - |
dc.contributor.googleauthor | In Hee Kim | - |
dc.contributor.googleauthor | Won Kim | - |
dc.contributor.googleauthor | Yoon Jun Kim | - |
dc.identifier.doi | 10.2147/JHC.S304439 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J03970 | - |
dc.identifier.eissn | 2253-5969 | - |
dc.identifier.pmid | 34169044 | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | prognosis | - |
dc.subject.keyword | sorafenib | - |
dc.subject.keyword | survival | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 8 | - |
dc.citation.startPage | 613 | - |
dc.citation.endPage | 623 | - |
dc.identifier.bibliographicCitation | JOURNAL OF HEPATOCELLULAR CARCINOMA, Vol.8 : 613-623, 2021-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.